LLY

1,091.31

+2.27%↑

JNJ

224.22

+0.46%↑

ABBV

219.21

+2.9%↑

UNH

383.21

+2.17%↑

MRK

115.28

-0.64%↓

LLY

1,091.31

+2.27%↑

JNJ

224.22

+0.46%↑

ABBV

219.21

+2.9%↑

UNH

383.21

+2.17%↑

MRK

115.28

-0.64%↓

LLY

1,091.31

+2.27%↑

JNJ

224.22

+0.46%↑

ABBV

219.21

+2.9%↑

UNH

383.21

+2.17%↑

MRK

115.28

-0.64%↓

LLY

1,091.31

+2.27%↑

JNJ

224.22

+0.46%↑

ABBV

219.21

+2.9%↑

UNH

383.21

+2.17%↑

MRK

115.28

-0.64%↓

LLY

1,091.31

+2.27%↑

JNJ

224.22

+0.46%↑

ABBV

219.21

+2.9%↑

UNH

383.21

+2.17%↑

MRK

115.28

-0.64%↓

Accueil・Liste d'Actions・REVOLUTION Medicines Inc

REVOLUTION Medicines Inc

Ouvert

SecteurSoins de santé

155.56 1.98

Acheter Vendre

Résumé

Variation du prix de l'action

24h

Actuel

Min

151.1

Max

155.35

Chiffres clés
By Trading Economics
Revenu	-89M -454M
BPA	-2.29
Employés	883
EBITDA	-92M -441M

Recommandations
By TipRanks
Recommandations	Achat Fort
Prévisions sur 12 Mois	+21.37% upside

Dividendes
By Dow Jones
Prochains Résultats	5 août 2026

Statistiques du Marché
By TradingEconomics
Capitalisation Boursière	3.4B 35B
Ouverture précédente	153.58
Clôture précédente	155.56

Sentiment de l'Actualité

By Acuity

50%

147 / 344 Classement par Healthcare

REVOLUTION Medicines Inc Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

26 janv. 2026, 11:10 UTC

Principaux Mouvements du Marché

Acquisitions, Fusions, Rachats

Revolution Medicines Shares Slide Premarket After Merck Talks Cool

7 janv. 2026, 20:13 UTC

Principaux Mouvements du Marché

AbbVie, Revolution Medicines Stocks Gain on Report of Possible Acquisition

17 oct. 2025, 18:13 UTC

Principaux Mouvements du Marché

Revolution Medicines Rises as FDA Grants Priority Designation for Cancer Treatment

26 janv. 2026, 09:55 UTC

Actions en Tendance

Stocks to Watch Monday: American Airlines, USA Rare Earth, RevMed -- WSJ

25 janv. 2026, 19:30 UTC

Acquisitions, Fusions, Rachats

Merck No Longer in Talks to Acquire Revolution Medicines, Sources Say -- WSJ

25 janv. 2026, 19:30 UTC

Acquisitions, Fusions, Rachats

Companies Had Been Discussing Roughly $30B Deal -- WSJ

25 janv. 2026, 19:30 UTC

Acquisitions, Fusions, Rachats

Merck No Longer in Talks to Buy Revolution Medicines -- WSJ

9 janv. 2026, 19:58 UTC

Acquisitions, Fusions, Rachats

Merck in Talks to Buy Revolution Medicines for Around $30 Billion -- WSJ

9 janv. 2026, 14:54 UTC

Acquisitions, Fusions, Rachats

Revolution Medicines Stock Jumps. Takeover Buzz Grows, Another Suitor Emerges. -- Barrons.com

9 janv. 2026, 10:54 UTC

Acquisitions, Fusions, Rachats

Revolution Medicines Stock Soars. Takeover Buzz Grows, Another Suitor Emerges. -- Barrons.com

8 janv. 2026, 14:49 UTC

Acquisitions, Fusions, Rachats

AbbVie Denies It's in Talks to Buy Revolution Medicines. Both Stocks Are Falling. -- Barrons.com

8 janv. 2026, 12:38 UTC

Acquisitions, Fusions, Rachats

AbbVie Denies It's in Talks to Buy Revolution Medicines. Both Stocks Are Falling. -- Barrons.com

7 janv. 2026, 22:43 UTC

Acquisitions, Fusions, Rachats

Revolution Medicines Draws Takeover Interest -- 2nd Update

7 janv. 2026, 20:29 UTC

Acquisitions, Fusions, Rachats

AbbVie Near Deal for Revolution Medicines -- Update

7 janv. 2026, 19:48 UTC

Acquisitions, Fusions, Rachats

Revolution Has Market Value of Around $16B -- WSJ

7 janv. 2026, 19:48 UTC

Acquisitions, Fusions, Rachats

AbbVie Near Deal for Revolution Medicines -- WSJ

7 janv. 2026, 19:48 UTC

Acquisitions, Fusions, Rachats

Deal May Come Soon, Sources Say -- WSJ

7 janv. 2026, 19:48 UTC

Acquisitions, Fusions, Rachats

AbbVie in Advanced Talks to Buy Revolution Medicines, Sources Say -- WSJ

Comparaison

Variation de prix

REVOLUTION Medicines Inc prévision

Objectif de Prix

By TipRanks

21.37% hausse

Prévisions sur 12 Mois

Moyen 183.65 USD 21.37%

Haut 263 USD

Bas 140 USD

Basé sur 21 analystes de Wall Street proposant des objectifs de prix à 12 mois pour Microsoft Corp. au cours des 3 derniers mois.

Note du Consensus

By TipRanks

Achat Fort

21 ratings

Achat

Maintien

Vente

Basé sur 21 qui ont noté l'action Microsoft Corp. au cours des 3 derniers mois.

Sentiment

By Acuity

147 / 344Classement par Soins de santé

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

Coût des ventes

Marge brute des ventes

Charges d'intérêt sur la dette

EBITDA

Bénéfice d'exploitation

À Propos REVOLUTION Medicines Inc

Revolution Medicines, Inc., a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company's research and development pipeline comprises RAS(ON) inhibitors designed to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors for combination treatment strategies. Its RAS(ON) inhibitors include RMC-6236 (multi), RMC-6291 (G12C), and RMC-9805 (G12D), which are in phase 1 clinical trial; and development candidates comprise RMC-5127 (G12V), RMC-0708 (Q61H), and RMC-8839 (G13C), as well as programs focused on G12R and other targets. The company's RAS companion inhibitors include RMC-4630 that is in phase 2 clinical trial; and RMC-5552, which is in phase 1 clinical trial. Revolution Medicines, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.